Barclays’s Terns Pharmaceuticals TERN Stock Holding History

Barclays’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.27K	Buy	+100	New	+$4.11K	﹤0.01%	4768
2024 Q4	–	Sell	-34,400	Closed	-$287K	–	5472
2024 Q3	$287K	Buy	+34,400	New	+$283K	﹤0.01%	4113

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Barclays's TERN Position: Q1 2026 in Review

Barclays increased its Terns Pharmaceuticals (TERN) stake by 291% in Q1 2026, buying an estimated $20.5M and bringing the position to 669,601 shares worth $35.3M. The position accounts for 0.01% of the portfolio, ranked #858.

Barclays first reported a position in TERN in Q1 2022 and has held it in 17 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Barclays held 669,601 shares of Terns Pharmaceuticals worth $35.3M as of Q1 2026.
Barclays bought 498,415 Terns Pharmaceuticals shares in Q1 2026, an estimated $20.5M.
Terns Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #858 holding.
Barclays first reported a position in Terns Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.